Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Decreased plasma omentin-1 levels in Type 1 diabetes mellitus

Tools
- Tools
+ Tools

Tan, Bee K., Pua, S., Syed, Farhatullah, Lewandowski, K. C., O'Hare, J. Paul and Randeva, Harpal S. (2008) Decreased plasma omentin-1 levels in Type 1 diabetes mellitus. Diabetic Medicine, Vol.25 (No.10). pp. 1254-1255. doi:10.1111/j.1464-5491.2008.02568.x

Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.1111/j.1464-5491.2008.02568.x

Request Changes to record.

Abstract

Context:The novel adipokine, nesfatin-1/NUCB-2, reduces food intake, levels of which are elevated in overweight individuals.

Objectives:The aim of the study was to investigate the mechanisms underlying brain nesfatin-1/NUCB-2 uptake and to determine whether reduced uptake may contribute to nesfatin-1/NUCB-2 resistance.

Design:Cerebrospinal fluid (CSF) and corresponding plasma nesfatin-1/NUCB-2 were measured by ELISA [18 men and 20 women; age, 19–80 yr; body mass index (BMI), 16.2–38.1 kg/m2] and correlated to body adiposity and metabolic parameters.

Results:CSF/plasma nesfatin-1/NUCB-2 ratio was significantly negatively associated with BMI, body weight, fat mass, and CSF glucose. BMI was predictive of CSF/plasma nesfatin-1/NUCB-2 ratio (β = −0.786; P = 0.045). CSF nesfatin-1/NUCB-2 was significantly positively associated with plasma nesfatin-1/NUCB-2 (R = 0.706; P < 0.01). There was a significant linear relation between CSF and plasma nesfatin-1/NUCB-2 in lean (BMI <25 kg/m2; R = 0.744; P = 0.002) and obese (BMI ≥30 kg/m2; R = 0.693; P = 0.026) subjects. Subjects in the highest plasma nesfatin-1/NUCB-2 quintile had lower CSF/plasma nesfatin-1/NUCB-2 ratio [26.5% (26.0–29.5%)] compared to the lowest plasma nesfatin-1/NUCB-2 quintile [38.5% (34.0–42.0%)] (P < 0.01), corresponding BMI [32.4 (31.0–35.0) vs. 23.3 (19.7–23.5) kg/m2; P < 0.01], and fat mass [32.8 (29.5–40.6) vs. 30.7 (8.2–20.1) kg/m2; P < 0.01].

Conclusions:Our observations have important implications with respect to the potential weight-reducing actions of nesfatin-1/NUCB-2 treatment. Future research should seek to clarify whether nesfatin-1/NUCB-2 would be beneficial in the management of obesity.

Item Type: Journal Item
Subjects: R Medicine > RC Internal medicine
Divisions: Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Diabetes, Insulin resistance, Adipose tissues
Journal or Publication Title: Diabetic Medicine
Publisher: Wiley-Blackwell Publishing Ltd.
ISSN: 0742-3071
Official Date: October 2008
Dates:
DateEvent
October 2008Published
Volume: Vol.25
Number: No.10
Number of Pages: 3
Page Range: pp. 1254-1255
DOI: 10.1111/j.1464-5491.2008.02568.x
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access
Funder: General Charities of the City of Coventry

Data sourced from Thomson Reuters' Web of Knowledge

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us